- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07940569
Glutamine Early Start in Children With SCD Younger Than Five (GLUT-5 SCD)
Safety and Efficacy of Glutamine in Preventing Vaso-occlusive Crisis Among Children With Sickle Cell Disease Younger Than Five
A study to assess the efficacy and safety of Glutamine in preventing Vaso Occlusive Crisis in pediatric population less than five years old
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Fatma S Ebeid, MD
- Phone Number: +201095569596
- Email: fatmaebeid@med.asu.edu.eg
Study Contact Backup
- Name: Nihal H Aly, MD
- Phone Number: +201001053961
Study Locations
-
-
-
Cairo, Egypt
- Faculty of Medicine Ain Shams Research Institute- Clinical Research Center
-
Contact:
- Fatma S E Ebeid, MD
- Phone Number: +201001053961
- Email: fatmaebeid@med.asu.edu.eg
-
Contact:
- Nihal H Aly, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age from 1-5 years
- children diagnosed with SCD based on clinical picture, CBC, reticulocyte count, markers of hemolysis and hemoglobin analysis by HPLC
Exclusion Criteria:
- Patients with clinically significant renal or liver disease
- Patients with any clinical evidence of infection
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Patients receiving standard of care
|
Standard of care in SCD therapy as Hydroxyurea |
|
Experimental: Patients receiving Glutamine
|
Standard of care in SCD therapy as Hydroxyurea L-Glutamine as an oral powder |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Assessment of safety of L-Glutamine in children with SCD younger than 5 years old
Time Frame: 52 weeks
|
Assessment of safety of L-Glutamine in children with SCD younger than 5 years old by assessing the adverse event |
52 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Assessment of efficacy of L-Glutamine in reducing the occurrence of VOCs
Time Frame: 52 weeks
|
Assessment of efficacy of L-Glutamine in reducing the occurrence of VOCs from baseline to week 52 |
52 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Fatma SE Ebeid, MD, Faculty of Medicine Ain Shams University
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Genetic Diseases, Inborn
- Hematologic Diseases
- Anemia, Hemolytic, Congenital
- Anemia, Hemolytic
- Anemia
- Hemoglobinopathies
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities
- Hemic and Lymphatic Diseases
- Anemia, Sickle Cell
- Health Services Administration
- Health Care Quality, Access, and Evaluation
- Amino Acids, Peptides, and Proteins
- Quality of Health Care
- Quality Indicators, Health Care
- Amino Acids
- Amino Acids, Basic
- Amino Acids, Diamino
- Amino Acids, Neutral
- Standard of Care
- Glutamine
Other Study ID Numbers
- FMASU P19/2025
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.